期刊文献+

Ⅲ、Ⅳ期乳腺癌的外科治疗 被引量:2

Surgical therapy of stage Ⅲ and Ⅳ breast carcinoma
暂未订购
导出
摘要 目的 探讨 、 期乳腺癌的外科治疗方法。方法 对 12 0例 、 期乳腺癌的外科治疗资料进行总结 ,并随访疗效。结果 行改良根治术的 88例 期患者总生存率为 84.1% ,无复发生存率为 79.5 %。行根治术的 2 0例 期患者总生存率为 80 % (χ2 =0 .196 ,P>0 .0 5 ) ,无复发生存率为 70 % (χ2 =0 .85 9,P>0 .0 5 )。对孤立远处转移的 期患者采用根治性外科治疗 ,取得了较好效果。结论  期乳腺癌应以外科治疗为主 ,多选择改良根治术。对孤立远处转移的 期患者 ,仍应采用根治性手术治疗。 Objective To discuss the surgical therapy about stage Ⅲand Ⅳ breast carcinoma. Method Therapeutic data of 120 patients with breast carcinoma on stageⅢor Ⅳ was summarized,and the patients were followed up.Results The overall survival rate(OS) of 88 stage Ⅲ patients who received modified radical mastectomy was 84.1%,relapse-free survival rate(RFS) was 79.5%,but in 20 stage Ⅲ patients who received radical mastectomy,the OS and RFS were 80% and 70% respectively.The stage Ⅳpatients who had isolated metastasis were treated by radical surgical therapy,the effect was better.Conclusions The stageⅢ patients with breast carcinoma should be mostly treated by surgical therapy,and modified radical mastectomy should be the initial choose. The stage Ⅳpatients who had isolated metastasis should be treated by radical surgical therapy. [
出处 《临床外科杂志》 2000年第5期268-269,共2页 Journal of Clinical Surgery
关键词 乳腺癌 外科手术 治疗 Breast carcinoma Surgical therapy
  • 相关文献

参考文献1

二级参考文献10

  • 1李俊.乳腺癌的新辅助化疗[J].国外医学(外科学分册),1997,24(1):29-31. 被引量:16
  • 2Wang HC, Lo SS. Future prospects of neoadjuvant chemotherapy in treatment of primary breast cancer, Semin Surg Oncol,1996:12:59.
  • 3Hayward JL, Rubens RD. Assessment of response to therapy in advanced breast cancer. Br J Cancer,1977,35,292.
  • 4Hunt KK, Ames FC, Singletary SE, et al. Locally advanced noninflammatory breast cancer, Surg Clin North Am, 1996,76:393.
  • 5Pinedo HM, Honkoop AH, Hoekman K. et al. Improved disease-free survival (DFS) of patients with locally advanced breast cancer(LABC) using prolonged dose intensive neoadjuvant doxorubicin (A), cyclophosphamide (C) and GM-CSF(meeting abstract). Proc Am Meet Am Soc Clin Oncol,1996,15 ; A88.
  • 6Lind MJ,Grambreii L, Cantwell BMJ, et al. The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer. Br J Cancer, 1995,71:610.
  • 7Olson JE. Management of nonresectable loeally advanced(stge I ) breast caneer;An ECOG trial. Breast Cancer Res Treat,1986,8:109.
  • 8Scholl SM, Fourquet A, Asselain B, et al, Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast conserving surgery ; Preliminary results of a randomized trial:S6. Eur J Cancer,1994,30:645.
  • 9Mauriac L, Durand M, Avril A, et al. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumor larger than 3 cm. Ann Oncol,1992,2:347.
  • 10Fisher B, Gunduz N, Saffer EA. et al. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res,1983,43:1488.

共引文献3

同被引文献5

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部